Next Article in Journal
Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
Next Article in Special Issue
Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways
Previous Article in Journal
Glibenclamide for the Treatment of Acute CNS Injury
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2013, 6(10), 1304-1321;

Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease

Wolfson Centre for Age-Related Diseases, Guy's Campus, King's College London, London SE1 1UL, UK
Author to whom correspondence should be addressed.
Received: 17 September 2013 / Revised: 6 October 2013 / Accepted: 8 October 2013 / Published: 11 October 2013
(This article belongs to the Special Issue Drug Repositioning)
Full-Text   |   PDF [145 KB, uploaded 11 October 2013]


Alzheimer’s Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There is an urgent need to develop and evaluate more effective pharmacological treatments. Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches. This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date. Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery. View Full-Text
Keywords: Alzheimer’s; repositioning; treatment; drug Alzheimer’s; repositioning; treatment; drug
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Corbett, A.; Williams, G.; Ballard, C. Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease. Pharmaceuticals 2013, 6, 1304-1321.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top